Clinical trials
Hepatitis C, Chronic clinical trials
Below are recruiting hepatitis c, chronic clinical trials, each written for real people, not researchers. We’re tracking 83 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT07454837RecruitingPhase 2/Phase 3
Switching to brelovitug for chronic hepatitis D patients on bulevirtide
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
GrazAges 18 years+ - NCT07342868RecruitingPhase 1
Single dose study for liver health
This trial tests a single dose of an experimental drug called pevifoscorvir in people with moderate liver problems and in healthy people. It aims to see how the body processes the drug and if it is safe.
Orlando, FloridaAges 18–75 - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT05937178Recruiting
Real-World Study to Optimize Hepatitis B Tablet Treatment
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hefei, AnhuiAges 18–80 - NCT03999723RecruitingPhase 2
Test azacitidine with vitamin C to improve DNA changes
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
AalborgAges 18 years+ - NCT05807932RecruitingPhase 1/Phase 2
Venetoclax added to conditioning before stem cell transplant
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
Aachen, North Rhine-WestphaliaAges 18 years+ - NCT04601428RecruitingEarly Phase 1
Liver artery treatment for certain liver cancer patients
This early-phase study tests a treatment delivered through the liver’s artery for people with intermediate or limited advanced liver cancer who can’t have surgery. It aims to control the cancer after prior targeted liver treatments didn’t work or the cancer grew again.
Tainan, North Dist.Ages 18 years+ - NCT06837766Recruiting
Blood filtering for severe liver failure with organ damage
This study tests a blood-filtering system called CytoSorb in people with severe liver failure that also affects other organs. It aims to see if removing toxins from the blood can help reduce damage and improve recovery.
Ancona, AnconaAges 18 years+ - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+ - NCT05068674RecruitingPhase 1
Stem cell heart muscle therapy for weak heart after prior heart attack
This Phase 1 study tests a treatment made from stem cells to grow heart muscle cells (“cardiomyocytes”) for people with long-lasting (chronic) heart weakness after a prior heart attack. It aims to see if the therapy can improve heart function and is safe in carefully selected patients.
Palo Alto, CaliforniaAges 21–80
Hear when a new Hepatitis C, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis c, chronic?
- Yes. Clin2 currently lists 83 recruiting hepatitis c, chronic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis c, chronic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis c, chronic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.